The Cyto-Mine® platform by Fluidic Sciences and Sphere Bio utilizes innovative picodroplet-based technology to capture and screen antibodies directly from entire B cell repertoires, maintaining cell viability and greatly enhancing efficiency.
Image Credit: Fluidic Sciences and Sphere Bio
In this eBook, Fluidic Sciences and Sphere Bio introduces a fast and reliable single B cell screening technique that identifies antibodies with specific antigenic properties, eliminating the need for the traditional, time-consuming hybridoma screening process.
Fluidic Sciences and Sphere Bio’ Cyto-Mine® platform, harnesses proprietary picodroplet-based technology to capture and screen antibodies directly from whole B cell repertoires, preserving cell viabilities and dramatically improving efficiencies.
This approach allows researchers to pinpoint antibody-secreting cells and isolate rare cells that produce antigen-specific antibodies within just two days, greatly speeding up the development process and reducing the time to market for new therapeutics.
Download the full eBook now to read more.
Image Credit: Fluidic Sciences and Sphere Bio
About Fluidic Sciences and Sphere Bio
Fluidic Sciences develops transformative in‑solution technologies for protein interaction analysis. Its flagship Fluidity One‑M instrument leverages Microfluidic Diffusional Sizing (MDS) to measure binding affinity, stoichiometry, size, and concentration without immobilization - directly in complex backgrounds such as serum, plasma, and lysate.
Sphere Bio is a brand of Fluidic Sciences. Its technology develops and manufactures single‑cell analysis and monoclonality assurance systems that enable researchers to find, analyze, and isolate the most valuable cells with speed and precision. Its proprietary picodroplet microfluidics and Cyto‑Mine® Chroma multiplexing platform power applications across antibody discovery, cell line development, cell engineering, and cell therapy.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.